Human and Mouse CD8+CD25+FOXP3+ Regulatory T Cells at Steady State and during Interleukin-2 Therapy

International audienceIn addition to CD4+ regulatory T cells (Tregs), CD8+ suppressor T cells are emerging as an important subset of regulatory T cells. Diverse populations of CD8+ T cells with suppressive activities have been described. Among them, a small population of CD8+CD25+FOXP3+ T cells is found both in mice and humans. In contrast to thymic-derived CD4+CD25+FOXP3+ Tregs, their origin and their role in the pathophysiology of autoimmune diseases (AIDs) are less understood. We report here the number, phenotype, and function of CD8+ Tregs cells in mice and humans, at the steady state and in response to low-dose interleukin-2 (IL-2). CD8+ Tregs represent approximately 0.4 and 0.1% of peripheral blood T cells in healthy humans and mice, respectively. In mice, their frequencies are quite similar in lymph nodes (LNs) and the spleen, but two to threefold higher in Peyer patches and mesenteric LNs. CD8+ Tregs express low levels of CD127. CD8+ Tregs express more activation or proliferation markers such as CTLA-4, ICOS, and Ki-67 than other CD8+ T cells. In vitro, they suppress effector T cell proliferation as well as or even better than CD4+ Tregs. Owing to constitutive expression of CD25, CD8+ Tregs are 20- to 40-fold more sensitive to in vitro IL-2 stimulation than CD8+ effector T cells, but 2–4 times less than CD4+ Tregs. Nevertheless, low-dose IL-2 dramatically expands and activates CD8+ Tregs even more than CD4+ Tregs, in mice and humans. Further studies are warranted to fully appreciate the clinical relevance of CD8+ Tregs in AIDs and the efficacy of IL-2 treatment

Trans-endocytosis of CD80 and CD86:a molecular basis for the cell-extrinsic function of CTLA-4

Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an essential negative regulator of T cell immune responses whose mechanism of action is the subject of debate. CTLA-4 shares two ligands (CD80 and CD86) with a stimulatory receptor, CD28. Here, we show that CTLA-4 can capture its ligands from opposing cells by a process of trans-endocytosis. After removal, these costimulatory ligands are degraded inside CTLA-4-expressing cells, resulting in impaired costimulation via CD28. Acquisition of CD86 from antigen-presenting cells is stimulated by T cell receptor engagement and observed in vitro and in vivo. These data reveal a mechanism of immune regulation in which CTLA-4 acts as an effector molecule to inhibit CD28 costimulation by the cell-extrinsic depletion of ligands, accounting for many of the known features of the CD28-CTLA-4 system

Treg and CTLA-4: Two intertwining pathways to immune tolerance.

Both the CTLA-4 pathway and regulatory T cells (Treg) are essential for the control of immune homeostasis. Their therapeutic relevance is highlighted by the increasing use of anti-CTLA-4 antibody in tumor therapy and the development of Treg cell transfer strategies for use in autoimmunity and transplantation settings. The CTLA-4 pathway first came to the attention of the immunological community in 1995 with the discovery that mice deficient in Ctla-4 suffered a fatal lymphoproliferative syndrome. Eight years later, mice lacking the critical Treg transcription factor Foxp3 were shown to exhibit a remarkably similar phenotype. Much of the debate since has centered on the question of whether Treg suppressive function requires CTLA-4. The finding that it does in some settings but not in others has provoked controversy and inevitable polarization of opinion. In this article, I suggest that CTLA-4 and Treg represent complementary and largely overlapping mechanisms of immune tolerance. I argue that Treg commonly use CTLA-4 to effect suppression, however CTLA-4 can also function in the non-Treg compartment while Treg can invoke CTLA-4-independent mechanisms of suppression. The notion that Foxp3 and CTLA-4 direct independent programs of immune regulation, which in practice overlap to a significant extent, will hopefully help move us towards a better appreciation of the underlying biology and therapeutic significance of these pathways

Factor XIIIA-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking

Lung cancer is the leading cause of cancer-related deaths worldwide, and lung squamous carcinomas (LUSC) represent about 30% of cases. Molecular aberrations in lung adenocarcinomas have allowed for effective targeted treatments, but corresponding therapeutic advances in LUSC have not materialized. However, immune checkpoint inhibitors in sub-populations of LUSC patients have led to exciting responses. Using computational analyses of The Cancer Genome Atlas, we identified a subset of LUSC tumors characterized by dense infiltration of inflammatory monocytes (IMs) and poor survival. With novel, immunocompetent metastasis models, we demonstrated that tumor cell derived CCL2-mediated recruitment of IMs is necessary and sufficient for LUSC metastasis. Pharmacologic inhibition of IM recruitment had substantial anti-metastatic effects. Notably, we show that IMs highly express Factor XIIIA, which promotes fibrin cross-linking to create a scaffold for LUSC cell invasion and metastases. Consistently, human LUSC samples containing extensive cross-linked fibrin in the microenvironment correlated with poor survival

Confusing signals: Recent progress in CTLA-4 biology

The mechanism of action of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) remains surprisingly unclear. Regulatory T (Treg) cells can use CTLA-4 to elicit suppression; however, CTLA-4 also operates in conventional T cells, reputedly by triggering inhibitory signals. Recently, interactions mediated via the CTLA-4 cytoplasmic domain have been shown to preferentially affect Treg cells, yet other evidence suggests that the extracellular domain of CTLA-4 is sufficient to elicit suppression. Here, we discuss these paradoxical findings in the context of CTLA-4-mediated ligand regulation. We propose that the function of CTLA-4 cytoplasmic domain is not to transmit inhibitory signals but to precisely control the turnover, cellular location, and membrane delivery of CTLA-4 to facilitate its central function: regulating the access of CD28 to their shared ligands

On the induction and function of Foxp3+ regulatory T cells

This thesis is based on three original papers with the overall aim to study the mechanisms of induction and function of Foxp3+CD4+CD25+ regulatory T cells. Regulatory T cells induce down-modulation of costimulatory molecules CD80 and CD86 on dendritic cells in vitro. In the first study we further show that the extent of down-modulation is functionally significant since regulatory T cell conditioned DCs induce poor T cell proliferation responses. We further show that down-modulation is induced rapidly and is dependent on CTLA-4, expressed by the regulatory T cells. Regulatory T cells have been reported to kill antigen-presenting cells. Yet we demonstrate here that down-modulation is not a result of selective killing of DCs expressing high level of costimulatory molecules. We propose that regulatory T cells down-modulate B7-molecules on DCs in a CTLA-4-dependent way, thereby enhancing suppression of T cell activity. Previous studies have demonstrated that anti-CD40L or anti-B7 require the presence of CD4+CD25+ regulatory T cells for induction of antigen specific hypo-responsiveness. Other tolerance strategies involving regulatory T cells have shown a dependency on IL-10. The objective of the second study was to investigate the role of Foxp3+regulatory T cells and IL-10 in the induction of transplant tolerance by treatment with CTLA4Ig, anti-CD40L and anti-LFA-1. We demonstrate here that neither T cell derived IL-10 nor the presence of regulatory T cells is essential for induction of graft acceptance in mice treated with costimulation blockade. However, CD4+ T cells depleted of regulatory cells convert into CD4+CD25+ T cells in the periphery of treated mice and histological analysis revealed accumulation of a high number of CD4+Foxp3+ T cells specifically in long term accepted grafts. Suggesting that CD4+Foxp3+ T cells may be involved in the long-term acceptance of allografts induced by costimulation blockade. Repeated immunization of mice with staphylococcal enterotoxin B (SEB) induces extensive deletion of target CD4+ T cells. Some target cells are however spared and become anergic. In the third study we report that the T cell anergy correlates with an increased proportion of Foxp3+ cells among target T cells, mainly caused by a reduced number of Foxp3- cells. The anergic CD4+ target T cells from rag-2 deficient TCR-transgenic mice was previously shown to contain regulatory T cells with distinct suppressor cell function. We show here that these anergic cells lack Foxp3-expression, but that cells from the rag-2 deficient animals can be induced to express this factor when appropriately stimulated in vivo or in vitro. These data indicate that the distinct suppressor cell function of the anergic CD4+ T cells from rag-2 deficient and rag-2 sufficient mice is due to differential Foxp3 expression by these cells. Further, the absence of Foxp3 expressing cells in naive rag-2 deficient TCR transgenic mice reveals the induction of functionally distinct regulatory cells by repeated SEB immunization

T-cell tolerance induced by repeated antigen stimulation: Selective loss of Foxp3(-) conventional CD4 T cells and induction of CD4 T-cell anergy.

Repeated immunization of mice with bacterial superantigens induces extensive deletion and anergy of reactive CD4 T cells. Here we report that the in vitro proliferation anergy of CD4 T cells from TCR transgenic mice immunized three times with staphylococcal enterotoxin B (SEB) (3x SEB) is partially due to an increased frequency of Foxp3(+) CD4 T cells. Importantly, reduced number of conventional CD25(-) Foxp3(-) cells, rather than conversion of such cells to Foxp3(+) cells, was the cause of that increase and was also seen in mice repeatedly immunized with OVA (3x OVA) and OVA-peptide (OVAp) (3x OVAp). Cell-transfer experiments revealed profound but transient anergy of CD4 T cells isolated from 3x OVAp and 3x SEB mice. However, the in vivo anergy was CD4 T-cell autonomous and independent of Foxp3(+) Treg. Finally, proliferation of transferred CD4 T cells was inhibited in repeatedly immunized mice but inhibition was lost when transfer was delayed, despite the maintenance of elevated frequency of Foxp3(+) cells. These data provide important implications for Foxp3(+) cell-mediated tolerance in situations of repeated antigen exposure such as human persistent infections